The ACR's Model Biologics Policy addresses the indications and limitations for coverage and/or medical necessity for a class of drugs known as modifying anti-rheumatic drugs as they pertain to rheumatic diseases.
The ACR's Model Biologics Policy can be used nationwide to reduce administrative burden among rheumatologists, patients and insurers, and allow physicians to properly treat patients without administrative delays.
Prior Authorizations
In an effort to make sure that the best care is provided to patients, the ACR has developed a standardized prior authorization form.
>>Click here for more information and to download the Prior Authorization Form
